Authors:
Address: Department of Cancer Biology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Journal:

Publication:

abstract

Postexposure treatment (PET) of wild-type rabies virus (RV)-infected mice with a live-attenuated triple-glycoprotein RV variant (TriGAS) promotes survival but does not prevent the pathogenic RV from invading and replicating in the brain. Successful PET is associated with the induction of a robust virus-neutralizing antibody response and clearance of the wild-type RV from brain tissues. Comparison of the transcriptomes of normal mouse brain with those of wild-type-RV-infected mice that had received either mock or TriGAS PET treatment revealed that many of the host genes activated in the mock-treated mice represent type I interferon (IFN) response genes. This indicates that RV infection induces an early type I IFN response that is unable to control the infection. In contrast, most of the activated genes in the brain of the RV-infected, TriGAS-treated mouse play a role in adaptive immunity, including the regulation of T cell activation, T cell differentiation, and the regulation of lymphocyte and mononuclear cell proliferation. These findings were confirmed by quantitative PCR (qPCR) array studies, which showed that 3 genes in particular, encoding chemokine ligand 3 (Ccl3), natural killer cell activator 2 (interleukin 12B [IL-12B]), and granzyme A (GzmA), were activated earlier and to a greater extent in the brains of RV-infected mice treated with TriGAS than in the brains of mock-treated mice. The activation of these genes, known to play key roles in the regulation of lymphocyte and mononuclear cell proliferation, is likely an important part of the mechanism by which TriGAS mediates its PET activity.

Related Articles
The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system.
PLoS Negl Trop Dis. 2009
The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system.
Hooper DC, Phares TW, Fabis MJ, Roy A. PLoS Negl Trop Dis. 2009 Oct 6; 3(10):e535. Epub 2009 Oct 6.
Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus.
Proc Natl Acad Sci U S A. 2009
Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus.
Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, Dietzschold B. Proc Natl Acad Sci U S A. 2009 Jul 7; 106(27):11300-5. Epub 2009 Jul 6.
Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system.
J Virol. 2005
Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system.
Wang ZW, Sarmento L, Wang Y, Li XQ, Dhingra V, Tseggai T, Jiang B, Fu ZF. J Virol. 2005 Oct; 79(19):12554-65.
Review Immunogenicity and safety of recombinant rabies viruses used for oral vaccination of stray dogs and wildlife.
Zoonoses Public Health. 2009
Review Immunogenicity and safety of recombinant rabies viruses used for oral vaccination of stray dogs and wildlife.
Faber M, Dietzschold B, Li J. Zoonoses Public Health. 2009 Aug; 56(6-7):262-9.
Review Rabies virus clearance from the central nervous system.
Adv Virus Res. 2011
Review Rabies virus clearance from the central nervous system.
Hooper DC, Roy A, Barkhouse DA, Li J, Kean RB. Adv Virus Res. 2011; 79:55-71.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster